Bone Cancer Pain
Jimenez-Andrade JM et al. - Over the last decade, progress has been made in laying the foundation for a mechanism-based understanding of the factors that drive bone cancer pain. Interestingly, several therapies that attenuate bone cancer pain may also reduce tumor growth and tumor-induced bone remodeling. Thus, bisphosphonates are commonly used to treat bone cancer pain, and other therapies including denosumab (anti-RANKL; Amgen), tanezumab (anti-NGF; Pfizer), and pregabalin (Pfizer) are in mid- to latestage
clinical trials. Currently, we are beginning to understand
the mechanisms that drive bone cancer. If this progress can be sustained and expanded, these advances have the potential to enlarge the repertoire of therapies available to treat bone cancer pain and significantly improve the quality of life, functional status, and survival of patients with bone cancer. [more...]
|
|
|
